Crescita Therapeutics Statistics
Total Valuation
CRRTF has a market cap or net worth of 6.41 million. The enterprise value is 717,766.
| Market Cap | 6.41M |
| Enterprise Value | 717,766 |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 18.94M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -4.25% |
| Shares Change (QoQ) | -0.49% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 16.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 5.02 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.34 |
| EV / Sales | 0.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.14 |
Financial Position
The company has a current ratio of 2.36, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.36 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.18 |
| Interest Coverage | -57.95 |
Financial Efficiency
Return on equity (ROE) is -18.52% and return on invested capital (ROIC) is -12.25%.
| Return on Equity (ROE) | -18.52% |
| Return on Assets (ROA) | -9.33% |
| Return on Invested Capital (ROIC) | -12.25% |
| Return on Capital Employed (ROCE) | -22.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.79 |
| Inventory Turnover | 1.81 |
Taxes
| Income Tax | -9,740 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.04% in the last 52 weeks. The beta is 1.19, so CRRTF's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | +10.04% |
| 50-Day Moving Average | 0.41 |
| 200-Day Moving Average | 0.54 |
| Relative Strength Index (RSI) | 48.90 |
| Average Volume (20 Days) | 19,847 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CRRTF had revenue of 12.61 million and -2.13 million in losses. Loss per share was -0.11.
| Revenue | 12.61M |
| Gross Profit | 6.22M |
| Operating Income | -2.38M |
| Pretax Income | -2.14M |
| Net Income | -2.13M |
| EBITDA | -1.75M |
| EBIT | -2.38M |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 5.94 million in cash and 499,530 in debt, giving a net cash position of 5.44 million.
| Cash & Cash Equivalents | 5.94M |
| Total Debt | 499,530 |
| Net Cash | 5.44M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 10.34M |
| Book Value Per Share | 0.54 |
| Working Capital | 6.24M |
Cash Flow
In the last 12 months, operating cash flow was 1.28 million and capital expenditures -1.50 million, giving a free cash flow of -228,894.
| Operating Cash Flow | 1.28M |
| Capital Expenditures | -1.50M |
| Free Cash Flow | -228,894 |
| FCF Per Share | n/a |
Margins
Gross margin is 49.36%, with operating and profit margins of -18.87% and -16.86%.
| Gross Margin | 49.36% |
| Operating Margin | -18.87% |
| Pretax Margin | -16.94% |
| Profit Margin | -16.86% |
| EBITDA Margin | -13.85% |
| EBIT Margin | -18.87% |
| FCF Margin | n/a |
Dividends & Yields
CRRTF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.25% |
| Shareholder Yield | n/a |
| Earnings Yield | -33.19% |
| FCF Yield | -3.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRRTF has an Altman Z-Score of -1.24 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.24 |
| Piotroski F-Score | 3 |